Temat: "Gastrointestinal Agents" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Exploring treatment of inflammatory bowel disease with infliximab in the Middle East and Northern Africa: An analysis of the HARIR observational cohort study.
Autorzy:: Alharbi O; Gastroenterology Section, King Khalid University Hospital, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Hamed W; Ain Shams University Hospital, Department of Tropical Medicine, Cairo, Egypt.
Salem O; Osama Ebada GI Center, Department of Internal Medicine, Alexandria, Egypt.
Taylor C; Janssen, Medical Affairs, Dubai, United Arab Emirates.
Besar A; Janssen, Medical Affairs, Dubai, United Arab Emirates.
Sharaf M; Janssen, Medical Affairs, Jeddah, Saudi Arabia.; Pokaż więcej
Źródło:: Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association [Saudi J Gastroenterol] 2023 May-Jun; Vol. 29 (3), pp. 164-170.
Typ publikacji:: Observational Study; Multicenter Study; Journal Article
MeSH Terms:: Biological Products*
Colitis, Ulcerative*/drug therapy
Colitis, Ulcerative*/epidemiology
Inflammatory Bowel Diseases*/drug therapy
Inflammatory Bowel Diseases*/epidemiology
Infliximab*/therapeutic use
Antibodies, Monoclonal*/therapeutic use
Gastrointestinal Agents*/therapeutic use
Humans ; Africa, Northern ; Cohort Studies ; Crohn Disease/drug therapy ; Crohn Disease/epidemiology ; Middle East/epidemiology ; Prospective Studies ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission.
Autorzy:: Parisio L; IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. . .
Settanni CR; IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. .
Varca S; IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome; Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy. .
Laterza L; IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. .
Lopetuso LR; IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome; Department of Medicine and Ageing Sciences, Center for Advanced Studies and Technology, Università degli Studi 'G. D'Annunzio', Chieti-Pescara, Italy. .
Napolitano D; IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. .
Schiavoni E; IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. .
Turchini L; IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. .
Fanali C; IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. .
Alfieri N; IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. .
Pizzoferrato M; IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. .
Papa A; IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome; Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy. .
Pafundi PC; Epidemiology and Biostatistics Research Core Facility, Gemelli Science and Technology Park, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy. .
Armuzzi A; IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milan; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. .
Gasbarrini A; IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome; Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy. .
Pugliese D; IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. .
Scaldaferri F; IBD UNIT - CEMAD (Centro malattie apparato digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, Rome; Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy. .; Pokaż więcej
Źródło:: Journal of gastrointestinal and liver diseases : JGLD [J Gastrointestin Liver Dis] 2023 Dec 22; Vol. 32 (4), pp. 452-459. Date of Electronic Publication: 2023 Dec 22.
Typ publikacji:: Journal Article
MeSH Terms:: Inflammatory Bowel Diseases*/diagnosis
Inflammatory Bowel Diseases*/drug therapy
Colitis, Ulcerative*/diagnosis
Colitis, Ulcerative*/drug therapy
Crohn Disease*/drug therapy
Humans ; Prospective Studies ; Gastrointestinal Agents/adverse effects ; Treatment Outcome ; Remission Induction

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: PD-1-positive cells contribute to the diagnosis of inflammatory bowel disease and can aid in predicting response to vedolizumab.
Autorzy:: Kim MK; Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Republic of Korea.
Jo SI; PrismCDX Co., Ltd., Hwaseong-Si, Republic of Korea.
Kim SY; Convergence Medicine Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea.
Lim H; Department of Internal Medicine, Hallym University Sacred Heart Hospital, University of Hallym College of Medicine, Anyang, Republic of Korea.
Kang HS; Department of Internal Medicine, Hallym University Sacred Heart Hospital, University of Hallym College of Medicine, Anyang, Republic of Korea.
Moon SH; Department of Internal Medicine, Hallym University Sacred Heart Hospital, University of Hallym College of Medicine, Anyang, Republic of Korea.
Ye BD; Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Republic of Korea.; Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Soh JS; Department of Internal Medicine, Hallym University Sacred Heart Hospital, University of Hallym College of Medicine, Anyang, Republic of Korea. .
Hwang SW; Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Republic of Korea. .; Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2023 Dec 04; Vol. 13 (1), pp. 21329. Date of Electronic Publication: 2023 Dec 04.
Typ publikacji:: Journal Article
MeSH Terms:: Colitis, Ulcerative*/diagnosis
Colitis, Ulcerative*/drug therapy
Inflammatory Bowel Diseases*/diagnosis
Inflammatory Bowel Diseases*/drug therapy
Humans ; Programmed Cell Death 1 Receptor ; Gastrointestinal Agents/therapeutic use ; Retrospective Studies ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healing.
Autorzy:: Sommer K; Department of Medicine, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Heidbreder K; Department of Medicine, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Kreiss L; Department of Medicine, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Institute of Medical Biotechnology, Department of Chemical and Biological Engineering (CBI), Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Dedden M; Department of Medicine, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Paap EM; Department of Medicine, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Wiendl M; Department of Medicine, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Becker E; Department of Medicine, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Atreya R; Department of Medicine, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Erlangen, Germany.
Müller TM; Department of Medicine, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Erlangen, Germany.
Atreya I; Department of Medicine, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Erlangen, Germany.
Waldner M; Department of Medicine, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Erlangen, Germany.
Schürmann S; Institute of Medical Biotechnology, Department of Chemical and Biological Engineering (CBI), Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Friedrich O; Department of Medicine, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Neurath MF; Department of Medicine, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Erlangen, Germany.
Zundler S; Department of Medicine, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Erlangen, Germany.; Pokaż więcej
Źródło:: Clinical and translational medicine [Clin Transl Med] 2023 Apr; Vol. 13 (4), pp. e1233.
Typ publikacji:: Clinical Study; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Gastrointestinal Agents*/immunology
Gastrointestinal Agents*/pharmacology
Gastrointestinal Agents*/therapeutic use
Inflammatory Bowel Diseases*/drug therapy
Inflammatory Bowel Diseases*/immunology
Inflammatory Bowel Diseases*/pathology
Integrins*/antagonists & inhibitors
Integrins*/immunology
Macrophages*/drug effects
Macrophages*/immunology
Macrophages*/pathology
Wound Healing*/drug effects
Wound Healing*/immunology
Animals ; Humans ; Mice ; Crohn Disease/drug therapy ; Crohn Disease/immunology ; Crohn Disease/pathology ; Monocytes/drug effects ; Monocytes/immunology ; Monocytes/pathology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn's Disease Comparing, between CT-P13 and Originator Infliximab.
Autorzy:: Park J; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Cheon JH; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Lee KM; Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
Kim YH; Division of Gastroenterology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ye BD; Department of Gastroenterology and Inflammatory Bowel Disease Center, University of Ulsan College of Medicine, Seoul, Korea.
Eun CS; Department of Internal Medicine, Hanyang University Guri Hospital, Guri, Korea.
Kim SH; Medical Science Division, Celltrion, Inc., Incheon, Korea.
Lee SH; Medical Science Division, Celltrion, Inc., Incheon, Korea.
Lee JH; Medical Science Division, Celltrion, Inc., Incheon, Korea.
Schreiber S; Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany.; Pokaż więcej
Źródło:: Gut and liver [Gut Liver] 2023 May 15; Vol. 17 (3), pp. 430-440. Date of Electronic Publication: 2022 Aug 17.
Typ publikacji:: Randomized Controlled Trial; Journal Article
MeSH Terms:: Crohn Disease*/drug therapy
Biosimilar Pharmaceuticals*/therapeutic use
Inflammatory Bowel Diseases*/drug therapy
Humans ; Infliximab/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Treatment Outcome ; Gastrointestinal Agents/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study.
Autorzy:: Pugliese D; CEMAD - IBD UNIT, Unità Operativa Complessa di Medicina Interna e Gastroenterologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, Rome, Italy.
Privitera G; Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
Crispino F; Riuniti Villa Sofia-Cervello Hospital, Internal Medicine e 2, IBD Unit Palermo, Palermo, Italy.
Mezzina N; Department of Biochemical and Clinical Science 'L. Sacco' ASST Fatebenefratelli Sacco-University of Milan, Milan, Italy.
Castiglione F; Gastroenterology, Federico II University Hospital, Naples, Campania, Italy.
Fiorino G; IBD Center, Gastroenterology, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy¸ Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Laterza L; CEMAD - IBD UNIT, Unità Operativa Complessa di Medicina Interna e Gastroenterologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, Rome, Italy.
Viola A; UOSD Malattie Intestinali Croniche, Dip. di Medicina Clinica e Sperimentale, Policlinico Messina, Sicily, Italy.
Bertani L; Gastroenterology and Digestive Endoscopy Department of Medical Specialties Apuane Hospital, Tuscany North-West ASL, Massa, Italy.
Caprioli F; Gastroenterology and Endoscopy Unit, La Fondazione IRCCS Ca' Granda Ospedale Maggiore di Milano Policlinico, Department of Pathophysiology and Transplantation, University of Milan, Milan, Lombardia, Italy.
Cappello M; Head IBD Clinic, Gastroenterology Section, Promise, University of Palermo, Sicily, Italy.
Barberio B; Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
Ricci C; Gastroenterology Unit, Spedali Civili Hospital, Department of Experimental and Clinical Sciences, University of Brescia, Brescia, Italy.
Balestrieri P; Unit of Digestive Disease of Campus Bio Medico University of Rome, Italy.
Daperno M; Gastroenterology Unit, Azienda Ospedaliera Ordine Mauriziano di Torino, Torino, Piemonte, Italy.
Pluchino D; Gastroenterology Unit, A.O.U. Policlinico 'Vittorio Emanuele', Catania, Italy.
Rizzello F; Department of Internal Medicine and Gastroenterology, Policlinico Sant'Orsola Malpighi, Bologna, Italy.
Scribano ML; Gastroenterology Unit, San Camillo Forlanini Hospital, Rome, Italy.
Sablich R; Gastroenterology Unit, Santa Maria degli Angeli Hospital, Pordenone, Italy.
Pastorelli L; Gastroenterology Unit, IRCCS Policlinico San Donato Research Hospital, Milan, Italy.
Manguso F; Gastoenterology Unit, AO A. Cardarelli, Via A. Cardarelli, 5, Naples, 80131, Italy.
Variola A; IBD Unit, IRCCS Sacro Cuore Don Calabria, Negrar di Valpolicella, Verona, Italy.
Di Sario A; Clinica di Gastroenterologia, Università Politecnica delle Marche, Ancona, Italy.; IBD-UNIT, and Dipartimento Gastroenterologico e dei Trapianti, Polo Ospedaliero-Universitario 'Umberto I-G.M. Lancisi- G. Salesi', Ancona, Italy.
Grossi L; G. D'Annunzio University-Digestive Physiopathology Ospedale Spirito Santo Pescara, Pescara, Italy.
Armuzzi A; IBD Center, IRCCS Humanitas Research Hospital, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Pokaż więcej
Corporate Authors:: IG‐IBD LIVE Study Group
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2022 Jul; Vol. 56 (1), pp. 95-109. Date of Electronic Publication: 2022 May 12.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Gastrointestinal Agents*/adverse effects
Inflammatory Bowel Diseases*/drug therapy
Aged ; Antibodies, Monoclonal, Humanized ; Chronic Disease ; Colitis, Ulcerative/drug therapy ; Crohn Disease/drug therapy ; Humans ; Prospective Studies ; Retrospective Studies ; Treatment Outcome ; Tumor Necrosis Factor Inhibitors

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Differences in Whole-Blood Transcriptional Profiles in Inflammatory Bowel Disease Patients Responding to Vedolizumab Compared with Non-Responders.
Autorzy:: Haglund S; Department of Biomedical and Clinical Sciences, Linköping University, 581 83 Linköping, Sweden.; Laboratory Medicine, Region Jönköping County, 551 85 Jönköping, Sweden.
Söderman J; Department of Biomedical and Clinical Sciences, Linköping University, 581 83 Linköping, Sweden.; Laboratory Medicine, Region Jönköping County, 551 85 Jönköping, Sweden.
Almer S; IBD-Unit, Division of Gastroenterology, Karolinska University Hospital, 171 76 Stockholm, Sweden.; Department of Medicine, Karolinska Institutet-Solna, 171 76 Stockholm, Sweden.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Mar 18; Vol. 24 (6). Date of Electronic Publication: 2023 Mar 18.
Typ publikacji:: Journal Article
MeSH Terms:: Inflammatory Bowel Diseases*/drug therapy
Inflammatory Bowel Diseases*/genetics
Colitis, Ulcerative*/drug therapy
Colitis, Ulcerative*/genetics
Crohn Disease*/drug therapy
Humans ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Treatment Outcome ; Gastrointestinal Agents/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in patients with inflammatory bowel disease.
Autorzy:: Richard N; Department of Gastroenterology, CHU Rouen, Rouen, France.; University of Rouen Normandie, INSERM, ADEN UMR 1073, Nutrition, Inflammation and Microbiota-Gut-Brain Axis, Rouen, France.
Vuitton L; Department of Gastroenterology, Besançon University Hospital, Besançon, France.
Fumery M; Department of Gastroenterology, Amiens University Hospital, Amiens, France.; Pokaż więcej
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (6), pp. 741-742.
Typ publikacji:: Letter; Comment
MeSH Terms:: Inflammatory Bowel Diseases*/drug therapy
Colitis, Ulcerative*/drug therapy
Humans ; Antibodies, Monoclonal, Humanized/therapeutic use ; Administration, Intravenous ; Gastrointestinal Agents/therapeutic use ; Treatment Outcome

Opinia redakcyjna

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance.
Autorzy:: Colman RJ; Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Department of Pediatric Gastroenterology and Nutrition, Amsterdam University Medical Centers - Location University of Amsterdam, Emma Children's Hospital, Amsterdam, The Netherlands.
Mizuno T; Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Fukushima K; Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Haslam DB; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.; Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Hyams JS; Division of Digestive Diseases, Hepatology and Nutrition, Connecticut Children's Medical Center, Cincinnati, Ohio, USA.
Boyle B; Division of Gastroenterology, Hepatology and Nutrition, Nationwide Children's Hospital, Columbus, Ohio, USA.
Noe JD; Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Wisconsin, Wauwatosa, Wisconsin, USA.
D'Haens GR; Gastroenterology and Hepatology, Amsterdam University Medical Centers - Location University of Amsterdam, Amsterdam, The Netherlands.
Van Limbergen J; Department of Pediatric Gastroenterology and Nutrition, Amsterdam University Medical Centers - Location University of Amsterdam, Emma Children's Hospital, Amsterdam, The Netherlands.; Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology Metabolism, University of Amsterdam, Amsterdam, The Netherlands.
Chun K; Esoterix, LabCorp, Burlington, North Carolina, USA.
Yang J; Esoterix, LabCorp, Burlington, North Carolina, USA.
Denson LA; Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Ollberding NJ; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.; Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Vinks AA; Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Minar P; Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.; Pokaż więcej
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (5), pp. 524-539. Date of Electronic Publication: 2022 Oct 31.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Inflammatory Bowel Diseases*
Colitis, Ulcerative*/drug therapy
Colitis, Ulcerative*/chemically induced
Humans ; Child ; Young Adult ; Adolescent ; Treatment Outcome ; Gastrointestinal Agents ; Antibodies, Monoclonal, Humanized/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study.
Autorzy:: Mitrova K; Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE a.s., Charles University in Prague, Prague, Czech Republic.; Department of Paediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
Pipek B; Digestive Diseases Centre, Hospital AGEL Vitkovice, Ostrava, Czech Republic.; 2nd Department of Internal Medicine-Gastroenterology and Geriatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Czech Republic.; Department of Internal Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Bortlik M; Department of Gastroenterology, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic.; Institute of Pharmacology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.; Department of Internal Medicine, 1st Faculty of Medicine and Central Military Hospital, Prague, Czech Republic.
Bouchner L; Department of Internal Medicine, Faculty of Medicine in Pilsen, Charles University in Prague, Czech Republic.
Brezina J; Department of hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Douda T; 2nd Department of Gastroenterology, University Hospital Hradec Kralove, Charles University-Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic.
Drasar T; IBD centre Turnov, Liberec Regional Hospital, Liberec, Czech Republic.
Klvana P; Beskydy Gastrocentre, Hospital Frydek-Mistek, Frýdek-místek, Czech Republic.
Kohout P; Endoscopy, Internal Department, Pardubice Hospital, Pardubice, Czech Republic.
Leksa V; Department of Medicine 1st Faculty of Medicine Charles University and Military University Hospital, Prague, Czech Republic.
Minarikova P; Department of Internal Medicine, 1st Faculty of Medicine and Central Military Hospital, Prague, Czech Republic.
Novotny A; 4th Internal Clinic, General University Hospital, Charles University, Prague, Czech Republic.
Svoboda P; Department of Internal Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Skorpik J; Department of Gastroenterology, Hospital Jihlava, Jihlava, Czech Republic.
Ulbrych J; 2nd Department of Internal Medicine, St. Anne's University Hospital Brno, Brno, Czech Republic.; SurGal Clinic, Brno, Czech Republic.
Veinfurt M; Department of Gastroenterology, Hospital Karlovy Vary, Karlov Vary, Czech Republic.
Zborilova B; Department of Gastroenterology, Hospital Karlovy Vary, Karlov Vary, Czech Republic.
Lukas M; Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE a.s., Charles University in Prague, Prague, Czech Republic.
Duricova D; Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE a.s., Charles University in Prague, Prague, Czech Republic.; Institute of Pharmacology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.; Pokaż więcej
Corporate Authors:: Czech IBD Working Group
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2022 Dec 05; Vol. 16 (12), pp. 1808-1815.
Typ publikacji:: Observational Study; Multicenter Study; Journal Article
MeSH Terms:: Inflammatory Bowel Diseases*/drug therapy
Ustekinumab*/adverse effects
Ustekinumab*/therapeutic use
Antibodies, Monoclonal, Humanized*/adverse effects
Antibodies, Monoclonal, Humanized*/therapeutic use
Female ; Humans ; Infant ; Infant, Newborn ; Pregnancy ; Placenta ; Pregnancy Outcome ; Prospective Studies ; Treatment Outcome ; Tumor Necrosis Factor Inhibitors/adverse effects ; Tumor Necrosis Factor Inhibitors/therapeutic use ; Gastrointestinal Agents/adverse effects ; Gastrointestinal Agents/therapeutic use ; Maternal Exposure

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Predictive value of infliximab trough levels in maintenance therapy for 5-year sustained clinical remission in patients with inflammatory bowel disease.
Autorzy:: Jalali Y
Gojdicova A
Sturdik I
Toth J
Koller T
Huorka M
Jalali M
Payer J
Hlavaty T; Pokaż więcej
Źródło:: Bratislavske lekarske listy [Bratisl Lek Listy] 2023; Vol. 124 (7), pp. 485-492.
Typ publikacji:: Observational Study; Journal Article
MeSH Terms:: Colitis, Ulcerative*
Crohn Disease*/drug therapy
Inflammatory Bowel Diseases*/drug therapy
Humans ; Infliximab/therapeutic use ; Cross-Sectional Studies ; Prospective Studies ; Gastrointestinal Agents/therapeutic use ; Drug Monitoring

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.
Autorzy:: Derikx LAAP; Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.; Inflammatory Bowel Disease Center, Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands.
Dolby HW; Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
Plevris N; Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
Lucaciu L; Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
Rees CS; Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
Lyons M; Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
Siakavellas SI; Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
Constantine-Cooke N; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK.; Centre for Genomics and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK.
Jenkinson P; Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
Su S; Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
O'Hare C; Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
Kirckpatrick L; Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
Merchant LM; Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
Noble C; Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
Arnott ID; Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
Jones GR; Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.; Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, UK.
Lees CW; Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.; Centre for Genomics and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2021 Dec 18; Vol. 15 (12), pp. 2011-2021.
Typ publikacji:: Journal Article; Observational Study
MeSH Terms:: Adalimumab/*therapeutic use
Biosimilar Pharmaceuticals/*therapeutic use
Gastrointestinal Agents/*therapeutic use
Inflammatory Bowel Diseases/*drug therapy
Adalimumab/administration & dosage ; Adolescent ; Adult ; Biosimilar Pharmaceuticals/administration & dosage ; Cohort Studies ; Databases, Factual ; Disease-Free Survival ; Female ; Gastrointestinal Agents/administration & dosage ; Humans ; Male ; Prospective Studies ; Retrospective Studies ; Scotland ; State Medicine ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study.
Autorzy:: Poullenot F; CHU de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépato-gastroentérologie et oncologie digestive, Bordeaux, France.
Amiot A; Département de Gastroentérologie, Hôpitaux Universitaires Henri Mondor, Creteil, France.
Nachury M; Univ. Lille, Institute for Translational Research in Inflammation, France.
Viennot S; Hepato-gastroenterology Department, CHU Caen, Caen, France.
Altwegg R; Department of Gastroenterology, Saint-Eloi Hospital, Montpellier, France.
Bouhnik Y; Gastroenterology and Nutrition Support Department, Department of Gastroenterology, Beaujon Hospital, Clichy, France.
Abitbol V; Hôpital Cochin AP-HP Gastro-entérologie, and Université de Paris, Paris, France.
Nancey S; Department of Gastroenterology, CHU, Lyon, France.
Vuitton L; Department of Gastroenterology, CHRU, Besançon, France.
Peyrin-Biroulet L; Gastroenterology Department, Nancy University Hospital, Université de Lorraine, Nancy, France.
Biron A; CHU Reims, Hôpital Robert Debré. Service Hépato-gastroentérologie et cancérologie digestive, Reims, France.
Fumery M; Department of Gastroenterology, CHU, Amiens, France.
Picon L; Hepato-gastroenterology Department, CHRU Tours-TROUSSEAU Hospital, Tours, France.
Vidon M; Departement of Gastroenterology, Hôpital Intercommunal de Créteil, Créteil, France.
Reenaers C; Hepato-gastroenterology Department, CHU Sart Tilman, Liège University, Liège, Belgium.
Serrero M; Hepato-gastroenterology Department, APHM Hôpital Nord, Marseille, France.
Savoye G; Department of Gastroenterology, Normandie University, Rouen University Hospital-Charles Nicolle, Rouen, France.
Beaugerie L; Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Hôpital Saint-Antoine, Department of Gastroenterology, Paris, France.
Rivière P; CHU de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépato-gastroentérologie et oncologie digestive, Bordeaux, France.
Laharie D; CHU de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépato-gastroentérologie et oncologie digestive, Bordeaux, France.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2022 Nov 01; Vol. 16 (10), pp. 1523-1530.
Typ publikacji:: Multicenter Study; Journal Article
MeSH Terms:: Inflammatory Bowel Diseases*/drug therapy
Neoplasms*/chemically induced
Humans ; Female ; Adolescent ; Male ; Cohort Studies ; Retrospective Studies ; Tumor Necrosis Factor Inhibitors ; Immunosuppressive Agents/therapeutic use ; Gastrointestinal Agents/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn's Disease: Results from the Phase 2 HUBBLE Study.
Autorzy:: Hyams JS; Connecticut Children's Medical Center, Hartford, CT, USA.
Turner D; Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.
Cohen SA; Children's Center for Digestive Health Care, Atlanta, GA, USA.
Szakos E; Borsod-A-Z County Central University Teaching Hospital, Velkey Laszlo Paediatric Health Centre, University of Miskolc, Miskolc, Hungary.
Kowalska-Duplaga K; Department of Paediatrics, Gastroenterology and Nutrition, Jagiellonian University Medical College, Kraków, Poland.
Ruemmele F; Université de Paris, APHP, Hôpital Necker Enfants Malades, Paediatric Gastroenterology, Paris, France.
Croft NM; Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London and The Royal London Children's Hospital, Barts Health NHS Trust, London, UK.
Korczowski B; Department of Paediatrics and Paediatric Gastroenterology, University of Rzeszów, Rzeszów, Poland.
Lawrence P; Takeda, Cambridge, MA, USA.
Bhatia S; Takeda, Cambridge, MA, USA.
Kadali H; Takeda, Cambridge, MA, USA.
Chen C; Takeda, Cambridge, MA, USA.
Sun W; Takeda, Cambridge, MA, USA.
Rosario M; Takeda, Cambridge, MA, USA.
Kabilan S; Takeda, Cambridge, MA, USA.
Treem W; Takeda, Cambridge, MA, USA.
Rossiter G; Takeda, Cambridge, MA, USA.
Lirio RA; Takeda, Cambridge, MA, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2022 Aug 30; Vol. 16 (8), pp. 1243-1254.
Typ publikacji:: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
MeSH Terms:: Colitis, Ulcerative*/chemically induced
Colitis, Ulcerative*/drug therapy
Crohn Disease*/chemically induced
Crohn Disease*/drug therapy
Inflammatory Bowel Diseases*/drug therapy
Antibodies, Monoclonal, Humanized ; Child ; Gastrointestinal Agents/adverse effects ; Gastrointestinal Agents/pharmacokinetics ; Humans ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
Autorzy:: Smith PJ; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Critchley L; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Storey D; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Gregg B; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Stenson J; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Kneebone A; Department of Gastroenterology, Aintree University Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Rimmer T; Department of Gastroenterology, Aintree University Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Burke S; Department of Gastroenterology, Aintree University Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Hussain S; Liverpool School of Medicine, University of Liverpool, Liverpool, UK.
Yi Teoh W; Liverpool School of Medicine, University of Liverpool, Liverpool, UK.
Vazeille S; Liverpool School of Medicine, University of Liverpool, Liverpool, UK.
Serna S; Department of Digestive Diseases, Kettering General Hospital, Kettering, UK.
Steel A; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Derbyshire E; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Collins P; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Dibb M; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Flanagan P; Department of Gastroenterology, Aintree University Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Probert C; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.; Molecular and Cellular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Verma AM; Department of Digestive Diseases, Kettering General Hospital, Kettering, UK.
Subramanian S; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.; Department of Gastroenterology, Addenbrookes Hospital, Cambridge, UK.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2022 Sep 08; Vol. 16 (9), pp. 1436-1446.
Typ publikacji:: Journal Article; Multicenter Study
MeSH Terms:: Biosimilar Pharmaceuticals*/therapeutic use
Colitis*/chemically induced
Colitis, Ulcerative*
Crohn Disease*/diagnosis
Inflammatory Bowel Diseases*/chemically induced
Inflammatory Bowel Diseases*/drug therapy
Antibodies, Monoclonal/adverse effects ; C-Reactive Protein/metabolism ; Cohort Studies ; Drug Substitution ; Gastrointestinal Agents/therapeutic use ; Humans ; Infliximab/therapeutic use ; Leukocyte L1 Antigen Complex ; Prospective Studies ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Therapeutic drug monitoring for biological medications in inflammatory bowel disease.
Autorzy:: Cogan RC; Section of Pediatric Gastroenterology, Department of Pediatric and Child Health, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
El-Matary BW; Section of Pediatric Gastroenterology, Department of Pediatric and Child Health, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
El-Matary WM; Section of Pediatric Gastroenterology, Department of Pediatric and Child Health, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.; Pokaż więcej
Źródło:: Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association [Saudi J Gastroenterol] 2022 Sep-Oct; Vol. 28 (5), pp. 322-331.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Drug Monitoring*
Inflammatory Bowel Diseases*/drug therapy
Inflammatory Bowel Diseases*/epidemiology
Adult ; Biological Warfare Agents ; Biomarkers ; Child ; Gastrointestinal Agents/therapeutic use ; Humans ; Infliximab

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.
Autorzy:: Volkers A; Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Straatmijer T; Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.; Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands.
Duijvestein M; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, The Netherlands.
Sales A; Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Levran A; Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
van Schaik F; University Medical Centre Utrecht, Utrecht, The Netherlands.
Maljaars J; Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands.
Gecse K; Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Ponsioen C; Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Grootjans J; Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Hanzel J; Department of Gastroenterology, UMC Ljubljana, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Tack G; Medical centre Leeuwarden, Leeuwarden, The Netherlands.
Jansen J; OLVG, Amsterdam, The Netherlands.
Hoentjen F; Department of Gastroenterology, Radboud University Medical Center, Nijmegen, The Netherlands.; Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Canada.
de Boer N; Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
van der Marel S; Haaglanden Medical Centre, The Hague, The Netherlands.
Dijkstra G; University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Oldenburg B; University Medical Centre Utrecht, Utrecht, The Netherlands.
Löwenberg M; Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
van der Meulen A; Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands.
D Haens G; Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.; Pokaż więcej
Corporate Authors:: IBD center Amsterdam and the Dutch Initiative on Crohn and Colitis
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2022 Sep; Vol. 56 (6), pp. 1044-1054. Date of Electronic Publication: 2022 Jul 23.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Colitis, Ulcerative*/chemically induced
Colitis, Ulcerative*/drug therapy
Crohn Disease*/chemically induced
Crohn Disease*/drug therapy
Inflammatory Bowel Diseases*/drug therapy
Antibodies, Monoclonal, Humanized ; Gastrointestinal Agents/therapeutic use ; Humans ; Phobic Disorders ; Prospective Studies ; Remission Induction ; Treatment Outcome
SCR Disease Name:: Belonephobia

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies.
Autorzy:: Fierens L; KU Leuven, Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Leuven, Belgium.
Liefferinckx C; Erasme Hospital ULB, Department of Gastroenterology, Brussels, Belgium.
Hoefkens E; Imelda General Hospital, Department of Gastroenterology, Bonheiden, Belgium.
Lobatòn T; University Hospital Ghent, Department of Gastroenterology, Ghent, Belgium.; Ghent University, Department of Internal Medicine and Pediatrics, Ghent, Belgium.
Dreesen E; KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.
Sabino J; KU Leuven, Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Leuven, Belgium.; University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium.
Ferrante M; KU Leuven, Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Leuven, Belgium.; University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2022 Aug 04; Vol. 16 (7), pp. 1059-1069.
Typ publikacji:: Journal Article
MeSH Terms:: Biosimilar Pharmaceuticals*/therapeutic use
Colitis, Ulcerative*/chemically induced
Colitis, Ulcerative*/drug therapy
Inflammatory Bowel Diseases*/chemically induced
Inflammatory Bowel Diseases*/drug therapy
Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Gastrointestinal Agents ; Humans ; Infliximab ; Marketing ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases.
Autorzy:: Kantasiripitak W; Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.
Outtier A; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.; Department of Chronic Diseases and Metabolism, University of Leuven, Leuven, Belgium.
Wicha SG; Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Hamburg, Germany.
Kensert A; Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.; Department of Chemical Engineering, Vrije Universiteit Brussels, Brussels, Belgium.
Wang Z; Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.
Sabino J; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.; Department of Chronic Diseases and Metabolism, University of Leuven, Leuven, Belgium.
Vermeire S; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.; Department of Chronic Diseases and Metabolism, University of Leuven, Leuven, Belgium.
Thomas D; Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.
Ferrante M; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.; Department of Chronic Diseases and Metabolism, University of Leuven, Leuven, Belgium.
Dreesen E; Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.; Pokaż więcej
Źródło:: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2022 Aug; Vol. 11 (8), pp. 1045-1059. Date of Electronic Publication: 2022 Jun 15.
Typ publikacji:: Clinical Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Inflammatory Bowel Diseases*/drug therapy
Infliximab*/pharmacokinetics
Infliximab*/therapeutic use
Colitis, Ulcerative/drug therapy ; Gastrointestinal Agents ; Humans ; Prospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study.
Autorzy:: Vande Casteele N; Division of Gastroenterology, Department of Medicine, University of California San Diego School of Medicine, La Jolla, California, USA.; Alimentiv, London, Ontario, Canada.
Sandborn WJ; Division of Gastroenterology, Department of Medicine, University of California San Diego School of Medicine, La Jolla, California, USA.
Feagan BG; Alimentiv, London, Ontario, Canada.
Vermeire S; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
Dulai PS; Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Yarur A; Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Roblin X; Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Priest-en-Jarez, France.
Ben-Horin S; Department of Gastroenterology, Sheba Medical Center, Tel HaShomer, and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Dotan I; Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel, and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Osterman MT; University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Rosario M; Takeda, Cambridge, Massachusetts, USA.
Osborn TM; Takeda, Chicago, Illinois, USA.
Panes J; Department of Gastroenterology, Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
Lindner D; Takeda, Zurich, Switzerland.
Agboton C; Takeda, Zurich, Switzerland.; Pokaż więcej
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2022 Aug; Vol. 56 (3), pp. 463-476. Date of Electronic Publication: 2022 Apr 27.
Typ publikacji:: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Colitis, Ulcerative*/chemically induced
Colitis, Ulcerative*/drug therapy
Crohn Disease*/chemically induced
Crohn Disease*/drug therapy
Inflammatory Bowel Diseases*/pathology
Adult ; Antibodies, Monoclonal, Humanized ; Bayes Theorem ; Female ; Gastrointestinal Agents ; Humans ; Male ; Remission Induction ; Retrospective Studies ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Gastrointestinal Agents"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język

Rok publikacji